AbbVie Inc. (0QCV.IL)
IOB · USD · Healthcare · Drug Manufacturers - General
$286.49 (-0.18%) as of
Key statistics
- Market cap
- 515.38B
- P/E (TTM)
- 58.95
- EPS (TTM)
- 4.86
- Dividend yield
- 4.05%
- 52-week range
- 186.49 – 295.00
- Beta
- 0.47
- Revenue (TTM)
- 56.02B
- Profit margin
- 15.50%
- Volume
- 1.75k
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- North Chicago, IL, United States
- Employees
- 50,000
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.
Related stocks
- AO World PLC (AOL.XC)
- AAK AB (AAKS.XC)
- SEA LTD SEA ADS REPRESENTING OR (0A3T.IL)
- JPM GREEN SOCIAL SUSTAINABLE BOND ACTIVE UCITS ETF - USD (DIST) USD (DIST) (JUGN.L)
- VIANET GROUP PLC ORD 10P (VNET.L)
- DERICHEBOURG SA DERICHEBOURG OR (0K8W.IL)
- KLOECKNER & CO SE KLOECKNER & C (0KVR.IL)
- POWER PROBE PLC ORD 0.1P (PWR.L)